---
title: "CMS monoclonal antibody injection \"MG-K10\" listing application accepted"
description: "CMS announced that its subsidiary, Demy Pharmaceuticals, along with its affiliates, has obtained the joint development rights and exclusive commercialization rights for the Class 1 new drug anti-IL-4R"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263529522.md"
published_at: "2025-10-30T13:12:19.000Z"
---

# CMS monoclonal antibody injection "MG-K10" listing application accepted

> CMS announced that its subsidiary, Demy Pharmaceuticals, along with its affiliates, has obtained the joint development rights and exclusive commercialization rights for the Class 1 new drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (generic name: Kemeiqibai monoclonal antibody injection, "MG-K10"). The application for marketing authorization in China has been accepted by the National Medical Products Administration of China. "MG-K10" is intended for the treatment of moderate to severe atopic dermatitis in adults who have poor control with topical medications or for whom topical treatments are not suitable

CMS (00867.HK) announced that its subsidiary, Demei Pharmaceutical, along with its affiliates, has obtained the joint development rights and exclusive commercialization rights for the Class 1 new drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (generic name: Kemeiqibai monoclonal antibody injection, "MG-K10"). The application for marketing authorization in China has been accepted by the National Medical Products Administration of China.

"MG-K10" is intended for the treatment of moderate to severe atopic dermatitis in adults who have inadequate control with topical medications or for whom topical treatments are not suitable

### Related Stocks

- [00867.HK - CMS](https://longbridge.com/en/quote/00867.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Insilico and CMS launch drug discovery collaborations for CNS diseases | Insilico Medicine has partnered with China Medical System (CMS) to launch AI drug discovery collaborations targeting cen | [Link](https://longbridge.com/en/news/275583451.md) |
| JSW MG Motor India Unveils MG MAJESTOR, D+ Segment SUV | JSW MG MOTOR INDIA UNVEILS MG MAJESTOR, D+ SEGMENT SUV | [Link](https://longbridge.com/en/news/275738598.md) |
| Restoring economic growth in Lebanon will require comprehensive reforms, IMF says | WASHINGTON, Feb 19 (Reuters) - Lebanon’s economy has shown resilience despite conflicts in the region, with tourism fuel | [Link](https://longbridge.com/en/news/276355421.md) |
| 11:30 ETInventHelp Inventors Develop New Vaporizer and Attachment (PTA-448) | InventHelp has announced the development of a new vaporizer and attachment called the SPLIF T, designed to allow users t | [Link](https://longbridge.com/en/news/276357553.md) |
| Nvidia Deepens India Push As AI Infrastructure Race Heats Up | Nvidia Corp. is expanding its presence in India through partnerships with Yotta Data Services and E2E Networks to enhanc | [Link](https://longbridge.com/en/news/276218932.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.